Edition:
United States

aTyr Pharma Inc (LIFE.O)

LIFE.O on Nasdaq

3.30USD
26 May 2017
Change (% chg)

-- (--)
Prev Close
$3.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
150,400
52-wk High
$4.45
52-wk Low
$2.10

Latest Key Developments (Source: Significant Developments)

aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - aTyr Pharma Inc :aTyr Pharma announces first quarter 2017 operating results.aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56.aTyr Pharma Inc- As of March 31, 2017, aTyr had $61.9 million in cash, cash equivalents and investments.aTyr Pharma- Continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into Q3 of 2018.Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma announces promising top-line results from Resolaris
Monday, 24 Apr 2017 07:30am EDT 

April 24 (Reuters) - Atyr Pharma Inc :Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy.Resolaris generally well-tolerated at doses up to 3.0 mg/kg once weekly in early onset facioscapulohumeral muscular dystrophy.Atyr believes observed safety results of Resolaris to date are supportive of further advancement of resolaris.  Full Article

aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53
Thursday, 16 Mar 2017 04:05pm EDT 

aTyr Pharma Inc : Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018 . Atyr pharma announces fourth quarter and year-end 2016 operating results . Qtrly net loss per share attributable to common stockholders$0.53 .Q4 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris
Tuesday, 28 Feb 2017 08:00am EST 

Atyr Pharma Inc :Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™.  Full Article

Atyr Pharma enters into $20 million credit facility
Monday, 21 Nov 2016 08:00am EST 

Atyr Pharma Inc : Intends to use additional capital to pay off existing indebtedness . Entered into a $20 million credit facility with Silicon Valley Bank and Solar Capital Ltd . Atyr Pharma will receive $10 million after execution of loan agreement . Atyr Pharma Inc - under terms, two additional $5 million tranches will be available to Atyr Pharma, subject to achievement of certain specified milestones .Atyr Pharma enters into $20 million credit facility.  Full Article

Atyr Pharma Inc qtrly loss per share $0.65
Wednesday, 10 Aug 2016 04:05pm EDT 

Atyr Pharma Inc : Atyr Pharma announces second quarter 2016 operating results . Atyr Pharma Inc qtrly loss per share $0.65 .Currently expect that our cash, cash equivalents and investments will be sufficient to fund our anticipated operations into 2018..  Full Article

Atyr Pharma qtrly loss per share $0.68
Wednesday, 11 May 2016 04:25pm EDT 

Atyr Pharma Inc : Qtrly loss per share $0.68 .Atyr pharma announces first quarter 2016 operating results.  Full Article

aTyr Pharma, Inc Announces Change in Leadership
Monday, 13 Jul 2015 04:00pm EDT 

aTyr Pharma, Inc:Says resignation of President and Chief Operating Officer Frederic Chereau to pursue other opportunities, effective immediately.  Full Article

More From Around the Web